

# Pocket Reference to Renal Anemia

Second edition

Iain C Macdougall



Springer Healthcare

# **Pocket reference to renal anemia**

Second edition

# Pocket reference to renal anemia

## Second edition

**Iain C Macdougall, BSc, MD, FRCP**

Consultant Nephrologist and Professor of Clinical Nephrology

Department of Renal Medicine

King's College Hospital

London, UK



**Springer** Healthcare

Published by Springer Healthcare Ltd, 236 Gray's Inn Road, London, WC1X 8HB, UK.

[www.springerhealthcare.com](http://www.springerhealthcare.com)

© 2013 Springer Healthcare, a part of Springer Science+Business Media.

First edition 2003

Second edition 2013

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

ISBN 978 1 908517 74 6

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Alla Zarifyan

Designer: Joe Harvey

Artworker: Sissan Mollerfors

Production: Marina Maher

Printed in Great Britain by Latimer Trend

# Contents

|   |            |
|---|------------|
| <b>Dedication</b>   | <b>vii</b> |
| <b>Author biography</b>   | <b>ix</b>  |
| <b>1 What is renal anemia?</b>  | <b>1</b>   |
| References  | 4          |
| <b>2 What is the cause of renal anemia?</b>   | <b>5</b>   |
| Erythropoietin deficiency   | 5          |
| Uremic inhibitors   | 7          |
| Inflammation  | 7          |
| Hepcidin  | 9          |
| Iron deficiency   | 10         |
| Hyperparathyroidism   | 10         |
| Aluminum toxicity   | 11         |
| Shortened red blood cell life span  | 12         |
| References  | 12         |
| <b>3 Stepwise approach to anemia management in patients<br/>    with chronic kidney disease</b> | <b>13</b>  |
| Step 1: Exclude other causes of anemia  | 14         |
| Step 2: Iron management   | 14         |
| Step 3: Erythropoiesis-stimulating agent therapy  | 14         |
| Step 4: Blood transfusions  | 14         |
| References  | 14         |
| <b>4 Excluding other causes of anemia</b>   | <b>15</b>  |
| Reticulocyte count  | 17         |
| References  | 19         |

|   |           |
|---|-----------|
| <b>5 Iron management</b>  | <b>21</b> |
| Iron deficiency: absolute versus functional                         | 21        |
| Detection of iron deficiency  | 22        |
| Iron supplementation: oral versus intravenous                       | 24        |
| References  | 27        |
| <b>6 Erythropoiesis-stimulating agent therapy</b>                   | <b>29</b> |
| Epoetins (including "biosimilars")                                  | 29        |
| Darbepoetin alfa  | 30        |
| Methoxypolyethylene glycol epoetin beta                             | 30        |
| Peginesatide  | 31        |
| Normal Hematocrit Trial, CREATE, CHOIR, and TREAT                   | 32        |
| Trigger hemoglobin concentration                                    | 34        |
| Target hemoglobin   | 34        |
| Erythropoiesis-stimulating agent therapy and the risk of malignancy | 35        |
| Erythropoiesis-stimulating agent therapy and the risk of stroke     | 36        |
| Poor response to erythropoiesis-stimulating agent therapy           | 38        |
| Adjuvant therapy  | 41        |
| References  | 41        |
| <b>7 Blood transfusions</b>   | <b>45</b> |
| References  | 47        |
| <b>8 Guidelines on the management of renal anemia</b>               | <b>49</b> |
| References  | 51        |
| <b>9 What is the future of renal anemia management?</b>             | <b>53</b> |
| Hypoxia-inducible factor stabilizers                                | 53        |
| Hepcidin modulation   | 54        |
| Other strategies  | 55        |
| References  | 55        |
| <b>10 Conclusions</b>   | <b>57</b> |
| <b>Dos and don'ts in renal anemia management</b>                    | <b>58</b> |
| <b>Learning points</b>  | <b>59</b> |
| References  | 61        |

# Dedication

Dedicated to my parents, Mary and Alasdair, my lovely wife, Penny, and our six children, Jennifer, Alan, Daniel, Inigo, Ella, and Nancy.